论文部分内容阅读
目的观察舒利迭治疗儿童中、重度哮喘的疗效和安全性。方法将121例3~14岁中、重度哮喘患儿随机分为治疗组和对照组。治疗组吸入糖皮质激素与长效β2受体激动剂舒利迭,1揿/次,2次/d;急性发作期间,同时吸入普米克令舒1 mg/2 m l+博利康尼雾化液5 mg/2 m l,1~2次/d,疗程2~6 d,病情控制后停用(即肺部听诊哮鸣音消失)。按常规阶梯治疗方案,吸入3个月,评价患儿临床表现、FEV1后降级治疗,改1揿/次,1次/d;3个月后再次评价,进入临床缓解期后,1揿/次,隔日1次,维持治疗;治疗期间监测最大呼气流量(PEF)或第1秒末用力呼气量(FEV1),疗程结束时对两组进行临床疗效判定。结果治疗组肺功能有明显改善(P<0.01)。FEV1均值治疗2 d后即显著上升;治疗后2~6 d FEV1改善率为98.5%。对照组为87.8%。两组比较,差异无统计学意义(P>0.01)。结论舒利迭治疗中、重度哮喘起效迅速,肺功能改善明显,无严重不良反应,患儿依从性好。
Objective To observe the efficacy and safety of seretide in children with moderate and severe asthma. Methods 121 cases of moderate and severe asthma children aged 3 to 14 years were randomly divided into treatment group and control group. Treatment group inhaled glucocorticoid and long-acting β2 receptor agonist Seretide, 1 揿 / times, 2 times / d; acute episode, inhalation of pulmicort 1 mg / 2 m l + 5 mg / 2 ml, 1 ~ 2 times / d, course of treatment of 2 ~ 6 d, the disease control disabled (ie, lung auscultation wheeze disappeared). According to the routine treatment plan, 3 months after inhalation, the clinical manifestations of children were evaluated, FEV1 was downgraded, changed 1 揿 / time, 1 time / d; 3 months after the revaluation, after entering the clinical remission, 1 揿 / time , And every other day to maintain the treatment. The maximum expiratory flow (PEF) or forced expiratory volume at the first second (FEV1) was monitored during the treatment. The clinical efficacy of the two groups was evaluated at the end of the treatment period. Results The lung function of the treatment group was significantly improved (P <0.01). After 2 days of treatment, the average value of FEV1 increased significantly; the improvement rate of FEV1 was 98.5% 2 to 6 days after treatment. The control group was 87.8%. There was no significant difference between the two groups (P> 0.01). Conclusion Seretide treatment of moderate and severe asthma rapid onset of significant improvement in lung function, no serious adverse reactions, children with good compliance.